Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

导出 OA

翻译打印收藏纠错

作者： Yves,Dauvilliers ^[1] ; Karel,Šonka ^[2] ; Richard K,Bogan ^[3] ; Markku,Partinen ^[4] ; Rafael,Del Rio Villegas ^[5] ; Nancy,Foldvary-Schaefer ^[6] ; Roman,Skowronski ^[7] ; Abby,Chen ^[7] ; Jed,Black ^[8] ; Franck,Skobieranda ^[9] ; Michael J,Thorpy ^[10]

作者单位： Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, 80 Avenue Augustin Fliche, 34295, Montpellier, France. y-dauvilliers@chu-montpellier.fr.;University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France. y-dauvilliers@chu-montpellier.fr. ^[1] Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. ^[2] University of South Carolina School of Medicine, Columbia, SC, USA. ^[3] Helsinki Sleep Clinic, Terveystalo Healthcare, Helsinki, Finland.;Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland. ^[4] Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid, Spain. ^[5] Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA. ^[6] Jazz Pharmaceuticals, Palo Alto, CA, USA. ^[7] Jazz Pharmaceuticals, Palo Alto, CA, USA.;Stanford University Center for Sleep Science and Medicine, Redwood City, CA, USA. ^[8] Jazz Pharmaceuticals, Philadelphia, PA, USA. ^[9] Albert Einstein College of Medicine, Bronx, NY, USA. ^[10]